Abstract:Antimicrobial resistance (AMR) is one of the greatest public health challenges of current time and it is majorly associated with Gram-negative bacterial infections. Among these infections, Klebsiella pneumoniae is the most notorious bacterial pathogen in the context of AMR. The inefficiency of currently available antibacterial drugs is becoming common in hospitalized patients and clinicians feel hopeless during treatment. Eventually, clinicians explore old regimes such as colistin to treat these multidrug resistance infections, however, unfortunately, the resistance towards these last-resort drugs is also emerging rapidly. In this study, we examined the occurrence of colistin resistance in Klebsiella pneumoniae concerning its mechanism of resistance, chronology, and geographical distribution. We found that resistance, towards these last-resort drugs, colistin and polymyxin B, is emerging rapidly with evolving multiple mechanisms of resistance. Although various attempts are being made to find a solution for this crisis, a combination therapy comprising approved antibacterial drugs may be one of the most suitable strategies to fight against AMR in the current time-ticking situation. Therefore, we evaluated the efficacy of a therapeutically viable combination of polymyxin B and triclosan using a set of standard antibacterial assays for in vitro preclinical efficacy. We found that the combination is highly effective in a colistin-resistant clinical strain of Klebsiella pneumoniae as triclosan sensitizes the pathogen towards polymyxin B. Furthermore, the results of additional complementary experiments such as time-kill kinetics, biofilm inhibition, frequency of resistance, cell viability, and cytotoxicity assays show very encouraging results for the feasibility and validation of this combination. Finally, we examined the presence of mutations in field isolates of Klebsiella pneumoniae FabI enzyme as it has been hypothesized previously that triclosan may cause mutation in its binding target, FabI. Interestingly, we could not detect any mutation in the triclosan binding site of FabI in the genome of field isolates. Altogether, this study provides an overview of the current situation on colistin resistance, a promising solution for colistin resistance comprising a combination of two already being used antibacterial ingredients based on in vitro preclinical efficacy studies.

In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole/Colistin Combination Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates.

In Vivo Emergence Of Colistin Resistance In Carbapenem-Resistant Klebsiella Pneumoniae Mediated By Premature Termination Of The Mgrb Gene Regulator

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Synergetic Effects of Combined Treatment of Colistin with Meropenem or Amikacin on Carbapenem-Resistant Klebsiella Pneumoniae in Vitro

In Vitro / Vivo Activity of Potential MCR-1 Inhibitor in Combination With Colistin Againsts mcr -1-Positive Klebsiella pneumonia .

In Vitro Antibacterial Effect of Fosfomycin Combination Therapy Against Colistin-Resistant Klebsiella Pneumoniae

Tigecycline in Combination with Other Antibiotics Against Clinical Isolates of Carbapenem-Resistant Klebsiella Pneumoniae in Vitro

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.

Assessing the efficacy of therapeutically promising combination of polymyxin B and triclosan against colistin resistant Klebsiella pneumoniae

[The Efficacy and Safety of Different Antimicrobial Regimens in Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections].

Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant Klebsiella pneumoniae

In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae

The Efficacy of Colistin Monotherapy Versus Combination Therapy with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter Baumannii ST2 Isolates.

Prevalence and molecular characteristics of colistin-resistant isolates among clinically isolated carbapenem-resistant Klebsiella pneumoniae in China

Combination Regimens with Colistin Sulfate Versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli

Solithromycin in Combination with Other Antimicrobial Agents Against the Carbapenem Resistant Klebsiella pneumoniae (CRKP)

In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli

Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae

In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, Aztreonam-Avibactam, and Comparators Toward Carbapenem-Resistant and Hypervirulent Klebsiella Pneumoniae Isolates.

In Vitro and in Vivo Synergistic Effects of Tigecycline Combined with Aminoglycosides on Carbapenem-Resistant Klebsiella Pneumoniae.

Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae